Johnson & Johnson: A Dirt-Cheap Stock to Buy Before the Fed Shakes Markets

With the Federal Reserve meeting looming this month, Wall Street is bracing for potential volatility. But one analyst sees this as an opportunity to scoop up shares of Johnson & Johnson (NYSE:JNJ) at a bargain price, arguing that the market is mispricing the healthcare giant.

The Analyst's Reasoning

The analyst believes Johnson & Johnson is not the slow, sleepy legacy name Wall Street prices it as. Instead, the company continues to demonstrate operational strength and product diversification, making its current valuation unjustifiably cheap. The analyst notes that investors are overly focused on inflation and interest rates, ignoring the company's solid fundamentals.

Context

This analysis comes amid heightened uncertainty over the Fed's rate path, with markets awaiting the central bank's decision. JNJ shares have experienced relatively modest volatility compared to the broader market, yet the stock still trades at a price-to-earnings multiple below its historical average.

What to Make of It

While the timing of a rebound is uncertain, Johnson & Johnson's strong fundamentals support the view that the stock is undervalued. Value-oriented investors may find the current volatility a suitable entry point.